Repository logo
 

C13orf31 (FAMIN) is a central regulator of immunometabolic function.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Type

Article

Change log

Authors

Cader, M Zaeem 
Boroviak, Katharina 
Zhang, Qifeng 
Assadi, Ghazaleh 
Kempster, Sarah L 

Abstract

Single-nucleotide variations in C13orf31 (LACC1) that encode p.C284R and p.I254V in a protein of unknown function (called 'FAMIN' here) are associated with increased risk for systemic juvenile idiopathic arthritis, leprosy and Crohn's disease. Here we set out to identify the biological mechanism affected by these coding variations. FAMIN formed a complex with fatty acid synthase (FASN) on peroxisomes and promoted flux through de novo lipogenesis to concomitantly drive high levels of fatty-acid oxidation (FAO) and glycolysis and, consequently, ATP regeneration. FAMIN-dependent FAO controlled inflammasome activation, mitochondrial and NADPH-oxidase-dependent production of reactive oxygen species (ROS), and the bactericidal activity of macrophages. As p.I254V and p.C284R resulted in diminished function and loss of function, respectively, FAMIN determined resilience to endotoxin shock. Thus, we have identified a central regulator of the metabolic function and bioenergetic state of macrophages that is under evolutionary selection and determines the risk of inflammatory and infectious disease.

Description

Keywords

Adenosine Triphosphate, Animals, Arthritis, Juvenile, Bacteriolysis, Cells, Cultured, Crohn Disease, Energy Metabolism, Fatty Acid Synthase, Type I, Genetic Predisposition to Disease, Humans, Infections, Inflammasomes, Intracellular Signaling Peptides and Proteins, Leprosy, Lipid Metabolism, Macrophages, Mice, Mice, Inbred C57BL, Mice, Knockout, NADPH Oxidases, Oxidation-Reduction, Polymorphism, Single Nucleotide, Proteins, Risk, Shock, Septic

Journal Title

Nat Immunol

Conference Name

Journal ISSN

1529-2908
1529-2916

Volume Title

Publisher

Springer Science and Business Media LLC
Sponsorship
Medical Research Council (MR/P011705/1)
Wellcome Trust (103077/Z/13/Z)
Wellcome Trust (106260/Z/14/Z)
European Research Council (260961)
Wellcome Trust (100891/Z/13/Z)
Wellcome Trust (100675/Z/12/Z)
Supported by the European Research Council under the European Community’s Seventh Framework Programme (FP7/2007-2013)/ERC Grant agreement 260961, the Wellcome Trust (investigator award 106260/Z/14/Z; a PhD fellowship for clinicians; and a Career Re-Entry Fellowship), the Wellcome Trust Sanger Institute, the US National Institutes of Health (5U420D011174 and 5U54HG006348), the Biotechnology and Biological Sciences Research Council, the National Institute for Health Research Cambridge Biomedical Research Centre, the European Crohn’s and Colitis Organisation and the Swedish Medical Research Council and the Olle Engkvist foundation.